Pneumococcal Infection

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

8100%

+ 20 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Sharp TherapeuticsPA - Pittsburgh

9 programs

PNEUMOVAX™ 23Phase 41 trial

Pneumococcal Vaccine, PolyvalentPhase 3Vaccine1 trial

V110Phase 31 trial

V116Phase 31 trial

+4 more programs

Active Trials

NCT04665050Completed102Est. Apr 2021

NCT07300267Recruiting210Est. May 2029

NCT00496093Completed133Est. Jan 2006

+6 more trials

MSDIreland - Ballydine

9 programs

PNEUMOVAX™ 23Phase 4

Pneumococcal Vaccine, PolyvalentPhase 3Vaccine

V110Phase 3

V116Phase 3

+4 more programs

Allergy TherapeuticsUK - West Sussex

2 programs

Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]Phase 2Vaccine1 trial

PNEUMOVAXN/A1 trial

Active Trials

NCT01307449Completed88Est. Jul 2017

NCT01654263Completed884Est. Aug 2015

PfizerNEW YORK, NY

1 program

13-valent Pneumococcal Conjugate VaccinePhase 1Vaccine1 trial

Active Trials

NCT01531322Completed72Est. Jan 2012

OrionUK - Cambridge

1 program

PnuBioVaxPhase 1

Orion PharmaUK - Reading

1 program

PnuBioVaxPhase 11 trial

Active Trials

NCT02572635Completed36Est. Sep 2016

Merck & Co.RAHWAY, NJ

5 programs

V118CPHASE_1

Pneumococcal Vaccine, PolyvalentPHASE_3Vaccine

V116PHASE_3

pneumococcal 23v polysaccharide vaccinePHASE_3Vaccine

PNEUMOVAX™ 23PHASE_4

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

Sharp TherapeuticsPNEUMOVAX™ 23

Sharp TherapeuticsV116

Sharp TherapeuticsV110

Sharp Therapeuticspneumococcal 23v polysaccharide vaccine

Sharp TherapeuticsPneumococcal Vaccine, Polyvalent

Allergy TherapeuticsPneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]

Sharp TherapeuticsV118C

Sharp TherapeuticsV116

Orion PharmaPnuBioVax

Pfizer13-valent Pneumococcal Conjugate Vaccine

Allergy TherapeuticsPNEUMOVAX

Clinical Trials (13)

Total enrollment: 6,824 patients across 13 trials

NCT02260882 Sharp TherapeuticsPNEUMOVAX™ 23

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Start: Oct 2014Est. completion: Apr 2015243 patients

Phase 4Completed

NCT06177912 Sharp TherapeuticsV116

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

Start: Jan 2024Est. completion: Feb 2025882 patients

Phase 3Completed

NCT05696080 Sharp TherapeuticsV116

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Start: Feb 2023Est. completion: Feb 2024518 patients

Phase 3Completed

NCT05425732 Sharp TherapeuticsV116

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Start: Jul 2022Est. completion: May 20232,663 patients

Phase 3Completed

NCT05158140 Sharp TherapeuticsV110

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Start: Jan 2022Est. completion: Feb 2023850 patients

Phase 3Completed

NCT00560950 Sharp Therapeuticspneumococcal 23v polysaccharide vaccine

Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

Start: Jul 2007Est. completion: May 2008143 patients

Phase 3Completed

NCT00496093 Sharp TherapeuticsPneumococcal Vaccine, Polyvalent

Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)

Start: Oct 2005Est. completion: Jan 2006133 patients

Phase 3Completed

NCT01654263 Allergy TherapeuticsPneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

Start: Oct 2012Est. completion: Aug 2015884 patients

Phase 2Completed

NCT07300267 Sharp TherapeuticsV118C

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

Start: Jan 2026Est. completion: May 2029210 patients

Phase 1Recruiting

NCT04665050 Sharp TherapeuticsV116

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

Start: Feb 2021Est. completion: Apr 2021102 patients

Phase 1Completed

NCT02572635 Orion PharmaPnuBioVax

A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax

Start: Oct 2015Est. completion: Sep 201636 patients

Phase 1Completed

NCT01531322 Pfizer13-valent Pneumococcal Conjugate Vaccine

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

Start: Oct 2011Est. completion: Jan 201272 patients

Phase 1Completed

NCT01307449 Allergy TherapeuticsPNEUMOVAX

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

Start: Apr 2014Est. completion: Jul 201788 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

12 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 6,824 patients

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.